Nabilone in Cannabis Users With PTSD
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Psychiatric, Psychiatric, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 21 - 45 |
| Updated: | 12/8/2018 |
| Start Date: | October 2015 |
| End Date: | August 2019 |
Effects of Nabilone on Trauma Related Cue Reactivity in Cannabis Users With PTSD
Despite the prevalence of cannabis use among the PTSD population and self-reports that it is
used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are
unknown. The purpose of this placebo-controlled, within-subject study is to assess the
effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the
primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in
cannabis smokers with PTSD.
used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are
unknown. The purpose of this placebo-controlled, within-subject study is to assess the
effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the
primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in
cannabis smokers with PTSD.
This study will compare the effects of smoked cannabis and nabilone on attentional bias
toward trauma- related stimuli, subjective and emotional processing to a range of trauma-and
non-trauma-related images and physiological reactivity to these stimuli in individuals with
CUD and PTSD. Importantly, this study will also probe the abuse related potential of nabilone
compared to smoked cannabis in this population, a critical aspect in determining the
potential feasibility for its use clinically to treat CUD in PTSD populations. The effects of
nabilone will be compared to propranolol as a positive control.
toward trauma- related stimuli, subjective and emotional processing to a range of trauma-and
non-trauma-related images and physiological reactivity to these stimuli in individuals with
CUD and PTSD. Importantly, this study will also probe the abuse related potential of nabilone
compared to smoked cannabis in this population, a critical aspect in determining the
potential feasibility for its use clinically to treat CUD in PTSD populations. The effects of
nabilone will be compared to propranolol as a positive control.
Inclusion Criteria:
- Current cannabis use
- PTSD symptoms
- Able to give informed consent and comply with study procedures
- Women who are normally cycling and practicing an effective form of birth control other
than hormonal contraceptives
Exclusion Criteria:
- Meeting criteria for certain current psychiatric disorders
- Clinical laboratory tests outside of normal limits
- History of clinically significant cardiac or respiratory diagnoses
- Current parole or probation
- Women who are currently pregnant or breastfeeding
We found this trial at
1
site
1051 Riverside Dr
New York, New York 10032
New York, New York 10032
646-774-5000
Phone: 646-774-7777
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials
